PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
ConditionPancreatic Cancer Non-resectable
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Paoli-Calmettes
About this trial
The study consists of a 25 ml blood sample collection:
* Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression
Collection of tumor material:
* During the initial diagnostic biopsy * On the operating room in case of surgery * At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification)
No previous treatment with surgery or chemotherapy
Age > 18 years
General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery)
Disqualifiers
Metastatic disease
Pancreatic tumor of a histological type other than adenocarcinoma
Other tumor under treatment or for which treatments have been completed for < 1 year
Pregnant or breastfeeding women
Trial design
Design model
Single group
Treatments tested in this trial
collection of blood and tumor samples
Other interventionThe study consists of the collection of a 25 ml blood sample: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression At the time of collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities.
Treatment groups
300 Participants
are divided into 1 treatment groupGroup A: collection of blood and tumor samplesOther 1 intervention
Trial outcomes
Primary outcomes
1
Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma
Analysis of the impact of identified biomarkers on overall patient survival and tumour response
Time frame
up to 6 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: